Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine · 2012 · 1.6K citations · Full text

Medicine, Nephrology, Pharmacology +14

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

Jonathan M. Shillingford, Noel Murcia, Claire H. Larson et al. · Proceedings of the National Academy of Sciences · 2006 · 798 citations · Full text

Medicine, Molecular Genetics, Nephrology +15

Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

Gerd Walz, Klemens Budde, Marwan Mannaa et al. · New England Journal of Medicine · 2010 · 577 citations · Full text

Medicine, Nephrology, Renal Pathology +15

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

Andreas L. Serra, Diane Poster, Andreas D. Kistler et al. · New England Journal of Medicine · 2010 · 563 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort1

Arlene B. Chapman, Lisa M. Guay‐Woodford, Jared J. Grantham et al. · Kidney International · 2003 · 416 citations · Full text

Medicine, Nephrology, Radiology +17